News about Clinical Trials

Avacta Group doses first patient in AVA6103 trial, advances targeted cancer therapy platform

Phase I FOCUS-01 study to evaluate novel peptide-drug conjugate across four solid tumours following Euro 10 million fundraise and collaboration with Tempus AI.

Clinical Trials | 11/04/2026 | By News Bureau |  358

Boehringer Ingelheim and BioNTech Partners to Test Novel Immunotherapy Combo in Aggressive Lung Cancer

The collaboration between Boehringer Ingelheim and BioNTech will evaluate a dual immuno-oncology approach in extensive-stage small cell lung cancer, aiming to improve outcomes in a disease with limited treatment options.

Clinical Trials | 11/04/2026 | By News Bureau |  121

Vanda Pharmaceuticals Launches Thetis Study to Test NEREUS for GLP-1 Agonist-Induced Vomiting

Vanda Pharmaceuticals launches Thetis study, a multicenter clinical trial testing NEREUS (oral tradipitant) to prevent vomiting in patients starting high-dose GLP-1 receptor agonists, evaluating safety and efficacy.

Clinical Trials | 09/04/2026 | By News Bureau |  201

GCAR and Purdue Pharma Launch Tinostamustine in GBM AGILE Trial

GCAR and Purdue Pharma LP initiate Tinostamustine enrolment in the GBM AGILE Phase 2/3 trial, advancing potential new treatment options for glioblastoma patients.

Clinical Trials | 09/04/2026 | By News Bureau

Sanofi's Lunsekimig Shows Promising Phase II Results in Asthma and Nasal Polyps Studies

The novel dual-targeting Nanobody met primary and key secondary endpoints in asthma and chronic rhinosinusitis trials, demonstrating improved outcomes and a favourable safety profile.

Clinical Trials | 08/04/2026 | By News Bureau |  110

CuraTeQ Biologics Announces Positive Phase 3 Results for BP11, Biosimilar to Xolair

CuraTeQ Biologics reports positive Phase 3 results for BP11, a biosimilar to Xolair, meeting primary endpoints in Chronic Spontaneous Urticaria (CSU) studies across Europe and India.

Clinical Trials | 07/04/2026 | By News Bureau |  148

Amgen Announces Positive Phase 3 Results for TEPEZZA

Amgen reports positive Phase 3 topline results for subcutaneous TEPEZZA in thyroid eye disease, with key endpoints met and 77 percent of patients achieving significant proptosis reduction.

Clinical Trials | 07/04/2026 | By News Bureau |  118

Medicus Pharma Submits Phase 2 Protocol to US FDA for Teverelix in Acute Urinary Retention

Medicus Pharma submits Phase 2 protocol to US FDA for Teverelix in acute urinary retention, targeting a USD 2 billion market with a mechanism-driven, capital-efficient development strategy.

Clinical Trials | 07/04/2026 | By News Bureau

Imfinzi Combo Improves PFS in Unresectable Liver Cancer in Phase 3 EMERALD-3 Trial

Imfinzi-based combination improves progression-free survival and shows a trend towards overall survival benefit in unresectable liver cancer in the Phase 3 EMERALD-3 trial.

Clinical Trials | 04/04/2026 | By News Bureau

Merck Initiates Phase 2b/3 Trial of MK-8748 for Neovascular Age-Related Macular Degeneration

Merck initiates a Phase 2b/3 trial of MK-8748 (Tiespectus), a bispecific antibody targeting Tie2 and VEGF pathways for treatment of neovascular age-related macular degeneration.

Clinical Trials | 04/04/2026 | By News Bureau |  174